What does Pharmaquest do?

Pharmaquest is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 17 January 2020, 1 establishment.

What is the address of Pharmaquest?

The registered office of Pharmaquest is located at Hoogstraat 10, 2580 Putte.

Is Pharmaquest still active?

Yes. According to the CBE (31 October 2026) Pharmaquest is active, legal situation “Normale toestand”, started on 17 January 2020.

Is Pharmaquest registered on Peppol?

Yes, Pharmaquest is registered on the Peppol network with ID 0208:0741703372.

What is the enterprise number of Pharmaquest?

The enterprise number of Pharmaquest is BE0741703372.

When was Pharmaquest founded?

Pharmaquest was founded on 17 January 2020.

Who are the directors of Pharmaquest?

According to the 2025 annual accounts, the directors of Pharmaquest are: Eva Hamelinck.

Is Pharmaquest a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 January 2020; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Pharmaquest make in 2025?

Pharmaquest posted a profit after taxes of € 239,015 in financial year 2025.

What is the revenue of Pharmaquest?

As a small company, Pharmaquest is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 325,985.

Pharmaquest (Private Limited) - Putte - BE0741703372

Dossier Pharmaquest, printed on 31 October 2026 from databakkes.be/en/0741703372/pharmaquest. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 56 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Pharmaquest from Putte, company number BE0741703372, closed financial year 2025 with a result of € 239,015 after tax. For that financial year Pharmaquest recorded a gross margin of € 325,985 and equity of € 34,187. Compared with financial year 2024, the result moved from € 80,263 to € 239,015. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 19, 2026.

What it is worth Healthy

€ 34,187

▼ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 239,015

▲ 198% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 160,928

▲ 75% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 239,278 paid out

100 % of the profit went to the shareholders, the rest stayed in the company.

Debts at end 2025

Bank debt ≈ 11 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.2 million

▼ 8% vs 2024

€ 106,699 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.

Owed to suppliers

€ 1,334

▲ 57% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 14,722

▼ 41% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 14,407 Gross margin 2022: € 14,407 First fiscal year in the series	€ 23,008 Gross margin 2023: € 23,008 ▲ 60% vs 2022 (€ 14,407) Favourable step	€ 120,486 Gross margin 2024: € 120,486 ▲ € 97,478 vs 2023 (€ 23,008) Favourable step	€ 325,985 Gross margin 2025: € 325,985 ▲ 171% vs 2024 (€ 120,486) Favourable step	▲ 171%
Profit after taxes	€ 8,909 Profit after taxes 2022: € 8,909 First fiscal year in the series	€ 16,932 Profit after taxes 2023: € 16,932 ▲ 90% vs 2022 (€ 8,909) Favourable step	€ 80,263 Profit after taxes 2024: € 80,263 ▲ € 63,331 vs 2023 (€ 16,932) Favourable step	€ 239,015 Profit after taxes 2025: € 239,015 ▲ 198% vs 2024 (€ 80,263) Favourable step	▲ 198%
Equity	€ 50,144 Equity 2022: € 50,144 First fiscal year in the series	€ 34,187 Equity 2023: € 34,187 ▼ 32% vs 2022 (€ 50,144) Unfavourable step	€ 34,450 Equity 2024: € 34,450 ▲ 1% vs 2023 (€ 34,187) Favourable step	€ 34,187 Equity 2025: € 34,187 ▼ 1% vs 2024 (€ 34,450) Unfavourable step	▼ 1%
Total debts	€ 12,062 Total debts 2022: € 12,062 First fiscal year in the series	€ 44,662 Total debts 2023: € 44,662 ▲ 270% vs 2022 (€ 12,062) Unfavourable step	€ 1,405,794 Total debts 2024: € 1,405,794 ▲ € 1.4 million vs 2023 (€ 44,662) Unfavourable step	€ 1,450,501 Total debts 2025: € 1,450,501 ▲ 3% vs 2024 (€ 1,405,794) Unfavourable step	▲ 3%
Cash	€ 46,221 Cash 2022: € 46,221 First fiscal year in the series	€ 77,934 Cash 2023: € 77,934 ▲ 69% vs 2022 (€ 46,221) Favourable step	€ 91,942 Cash 2024: € 91,942 ▲ 18% vs 2023 (€ 77,934) Favourable step	€ 160,928 Cash 2025: € 160,928 ▲ 75% vs 2024 (€ 91,942) Favourable step	▲ 75%
Retained profit	€ 47,144 Retained profit 2022: € 47,144 First fiscal year in the series	€ 31,187 Retained profit 2023: € 31,187 ▼ 34% vs 2022 (€ 47,144) Unfavourable step	€ 31,450 Retained profit 2024: € 31,450 ▲ 1% vs 2023 (€ 31,187) Favourable step	€ 31,187 Retained profit 2025: € 31,187 ▼ 1% vs 2024 (€ 31,450) Unfavourable step	▼ 1%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 32,889 Dividend 2023: € 32,889 Unchanged (€ 0) Unchanged	€ 80,000 Dividend 2024: € 80,000 ▲ 143% vs 2023 (€ 32,889) Unchanged	€ 239,278 Dividend 2025: € 239,278 ▲ 199% vs 2024 (€ 80,000) Unchanged	▲ 199%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 1,280,339 Bank debt 2024: € 1,280,339 Unchanged (€ 0) Unfavourable step	€ 1,173,690 Bank debt 2025: € 1,173,690 ▼ 8% vs 2024 (€ 1,280,339) Favourable step	▼ 8%
Balance sheet total	€ 62,206 Balance sheet total 2022: € 62,206 First fiscal year in the series	€ 78,849 Balance sheet total 2023: € 78,849 ▲ 27% vs 2022 (€ 62,206) Unchanged	€ 1,440,245 Balance sheet total 2024: € 1,440,245 ▲ € 1.4 million vs 2023 (€ 78,849) Unchanged	€ 1,484,688 Balance sheet total 2025: € 1,484,688 ▲ 3% vs 2024 (€ 1,440,245) Unchanged	▲ 3%

Key figures of Pharmaquest, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Pharmaquest?

What happened at Pharmaquest in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 19, 2026 New annual accounts for financial year 2025: profit of € 239,015 (▲ 198% vs 2024). Source: NBB ↗
Jan 17, 2020 New establishment in Putte. KBO
2020 Eva Hamelinck became a director. NBB
Jan 17, 2020 Start of the company according to the CBE. KBO

In short

From € 8,909 profit in 2022 to € 239,015 profit in 2025.

Paid € 74,170 in corporate taxes since 2022.

Best year ever: 2025, with € 239,015 profit.

Paid out € 352,167 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Eva Hamelinck

Pharmaquest

Apotheek I. De Bauw 99.5%

Behind Pharmaquest is Eva Hamelinck. It owns 99.5% of Apotheek I. De Bauw itself.

Directors

According to the 2025 annual accounts

Eva Hamelinck

Director

Also active at: APOTHEEK I. DE BAUW

since 2020

Establishments

Establishment units

Physical locations of this company

Registered office

Hoogstraat 10

2580 Putte

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

DIME

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0741.703.372

VAT number

BE 0741.703.372

Registered office

Hoogstraat 10, 2580 Putte

Names & denominations

Pharmaquest

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

17 January 2020

Peppol

Active · Active since 21 Nov 2025

Activities · NACE

Activiteiten van holdings

Holdings

Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

Pharmaquest

Warning lights

Financials

What happened to Pharmaquest?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions